CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (Nasdaq:DYAX) announced presentation of an integrated analysis of the two DX-88 Phase 3 studies demonstrating that treatment with DX-88 (ecallantide) provided clinically meaningful, rapid and sustained relief of symptoms in acute attacks of hereditary angioedema (HAE), when compared to placebo. This analysis, which included 143 unique patients treated with DX-88 or placebo, reinforces the robust efficacy findings seen for DX-88 in both its Phase 3 studies.
